10x Genomics Inc. Class A Company Profile
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
Market open · Delayed 15 min · as of Oct 8, 1:30 PM ET
10x Genomics at a glance
10x Genomics Inc. Class A (NASDAQ: TXG) is a Biotechnology: Laboratory Analytical Instruments company in the Industrials sector headquartered in Pleasanton, CA. 10x Genomics is led by Dr. Serge Saxonov Ph.D. and employs about 1,178 people. The company's shares have traded publicly since 2019.
At a market capitalization of $9.92 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001770787, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does 10x Genomics do?
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Business description based on the company's public filings.
Company information
- Legal name
- 10x Genomics Inc. Class A
- Ticker
- NASDAQ: TXG
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Serge Saxonov Ph.D.
- Employees
- 1,178
- Headquarters
- 6230 Stoneridge Mall Road, Pleasanton, CA, United States
- Phone
- 925 401 7300
- Website
- 10xgenomics.com
- IPO year
- 2019
- Market cap
- $9.92B
- SEC CIK
- 0001770787
Companies similar to 10x Genomics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIOBio-Rad Laboratories Inc. Class A | 358.78 | -2.48% | $9.59B | vs TXG |
| AVTRAvantor Inc. | 15.27 | -0.55% | $10.32B | vs TXG |
| BRKRBruker Corporation | 57.82 | -3.19% | $8.81B | vs TXG |
| RVTYRevvity Inc. | 150.30 | -2.15% | $16.77B | vs TXG |
| ALMRAlamar Biosciences Inc. | 26.43 | -4.84% | $1.83B | vs TXG |
| PACBPacific Biosciences of California Inc. | 2.22 | -18.38% | $690.04M | vs TXG |
| CTKBCytek Biosciences Inc. | 5.29 | -0.94% | $687.61M | vs TXG |
| EYPTEyePoint Inc. | 3.37 | +1.36% | $282.13M | vs TXG |